Therapeutic efficacy of artemether-lumefantrine and molecular markers of antimalarial resistance in Niger, 2022.

ABSTRACT:

Background

From August to October 2022, a therapeutic efficacy study of Niger's first-line antimalarial, artemether-lumefantrine (AL), was conducted in four sites (Aderbissinat, Boboye, Aguié, and Baban Tabki) to evaluate its therapeutic efficacy and investigate for molecular markers of antimalarial drug resistance.

Methods

Children aged 5 to 15 years old with uncomplicated malaria were assessed in a 28 day in vivo efficacy study. Genotyping using three markers (msp1, msp2 and the PolyA microsatellite) and match counting using the WHO three-out-of-three algorithm, were used to distinguish recrudescences from new infections. A two-out-of-three algorithm was also utilized as a sensitivity analysis.

Results

PCR uncorrected and corrected efficacy results at day 28 were ca

SUBMITTER: Laminou IM 

PROVIDER: S-EPMC12752158 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature